November 1, 2021 GBS Inc. to Present First Quarter 2022 Financial Results and Recent Corporate Update on November 11 November 1, 2021 GBS Inc. Announces Executive Leadership Changes to Accelerate Product Development and Manufacturing October 13, 2021 GBS Inc. Announces its Pre-Submission package is with the FDA September 7, 2021 GBS Inc. to Present at Upcoming September Virtual Investor Conferences August 11, 2021 GBS Inc. Reports Fourth Quarter and Full Year 2021 Preliminary Financial Results and Recent Business Highlights July 29, 2021 GBS Inc. to Present Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Update on August 11 July 26, 2021 GBS Inc. Engages L.E.K. Consulting Hong Kong Pty Limited to Identify Potential Sublicensees in China for its Saliva-Glucose Diabetes Test July 8, 2021 GBS Awarded $4.7 Million Australian Federal Government Science Grant To Manufacture Biosensor Technology June 8, 2021 Patients Living With Diabetes Voice Eagerness for ‘Finger-Prick’ Alternative in Global Glucose Monitoring Survey May 14, 2021 GBS Inc. Reports Third Quarter 2021 Financial Results and Recent Business Highlights
November 1, 2021 GBS Inc. to Present First Quarter 2022 Financial Results and Recent Corporate Update on November 11
November 1, 2021 GBS Inc. Announces Executive Leadership Changes to Accelerate Product Development and Manufacturing
August 11, 2021 GBS Inc. Reports Fourth Quarter and Full Year 2021 Preliminary Financial Results and Recent Business Highlights
July 29, 2021 GBS Inc. to Present Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Update on August 11
July 26, 2021 GBS Inc. Engages L.E.K. Consulting Hong Kong Pty Limited to Identify Potential Sublicensees in China for its Saliva-Glucose Diabetes Test
July 8, 2021 GBS Awarded $4.7 Million Australian Federal Government Science Grant To Manufacture Biosensor Technology
June 8, 2021 Patients Living With Diabetes Voice Eagerness for ‘Finger-Prick’ Alternative in Global Glucose Monitoring Survey